BioMarin Pharma (BMRN) Misses Q2 EPS by 5c, Revenue Beats
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.64 --0%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
ELWT, CAAP, RNW, More
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
ELWT, CAAP, RNW, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $430 million versus the consensus estimate of $418.61 million.
GUIDANCE:
BioMarin Pharma sees 2020 revenue of $1.85-1.95 billion, versus the consensus of $1.9 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
